Press releases

^{Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.}

YearType

2025

17 Jul 2025, 07:00 | Regulatory

Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results

· Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest debt.
· As compared to prior year Q2 IDEFIRIX product sales increased 76%.

8 Jul 2025, 08:00

Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer

3 Jul 2025, 08:00

Hansa Biopharma to host Q2 2025 interim results conference call

30 Jun 2025, 08:00

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

30 Jun 2025, 07:00 | Regulatory

Hansa Biopharma: Increase in number of shares and votes

25 Jun 2025, 16:00 | Regulatory

Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)

19 Jun 2025, 01:20 | Regulatory

Hansa Biopharma has carried out a directed cash share issue of approx. mSEK 232 and entered into binding agreement to restructure debt held by NovaQuest, including set-off issue of USD 14.9 million